Reasons for modification and discontinuation of antiretrovirals : results from a single treatment centreMOCROFT, Amanda; YOULE, Michael; JOHNSON, Margaret A et al.AIDS (London). 2001, Vol 15, Num 2, pp 185-194, issn 0269-9370Article

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trialsERON, Joseph J; YOUNG, Benjamin; KUMAR, Princy N et al.Lancet (British edition). 2010, Vol 375, Num 9712, pp 396-407, issn 0140-6736, 12 p.Article

Use of a stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance developmentPHILLIPS, Andrew N; YOULE, Michael; JOHNSON, Margaret et al.AIDS (London). 2001, Vol 15, Num 17, pp 2211-2220, issn 0269-9370Article

Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individualsSCHIPANI, Alessandro; WYEN, Christoph; ROCKSTROH, Jürgen et al.Journal of antimicrobial chemotherapy (Print). 2011, Vol 66, Num 6, pp 1332-1339, issn 0305-7453, 8 p.Article

CD4 cell count changes in individuals with counts above 500 cells/mm and viral loads below 50 copies/ml on antiretroviral therapyPHILLIPS, Andrew N; YOULE, Michael; LAMPE, Fiona et al.AIDS (London). 2002, Vol 16, Num 7, pp 1073-1075, issn 0269-9370Article

Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infectionBOOTH, Clare L; GARCIA-DIAZ, Ana M; YOULE, Michael S et al.Journal of antimicrobial chemotherapy (Print). 2007, Vol 59, Num 3, pp 517-524, issn 0305-7453, 8 p.Article

Theoretical rationale for the use of sequential single-drug antiretroviral therapy for treatment of HIV infectionPHILLIPS, Andrew N; YOULE, Michael S; LAMPE, Fiona et al.AIDS (London). 2003, Vol 17, Num 7, pp 1009-1016, issn 0269-9370, 8 p.Article

Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppressionPHILLIPS, Andrew N; STASZEWSKI, Schlomo; MILLER, Veronica et al.The Journal of infectious diseases. 2002, Vol 186, Num 8, pp 1086-1091, issn 0022-1899, 6 p.Article